ClinicalTrials.gg
CompletedNCT00662558Updated Feb 21, 2021Results posted

A Six Week Study Of The Pain Relieving Effects Of Celecoxib 200 Mg Twice Daily Compared To Tramadol 50 Mg Four Times Daily In Patients With Chronic Low Back Pain

A Phase 3 interventional study of celecoxib and tramadol HCL in Low Back Pain, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 60 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-21.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
802
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 711 studies in Low Back Pain with a site in United States — 99 open to participants now, 125 under way, 3 of them phase 3. Low Back Pain · United States.

Enrollment
26th of 623
802 · median 79
Started
2008
with 20 others
Phase 3
62 of 711
1 open now
Registered
86th of 711
by date

Among the 711 studies in Low Back Pain with a site in United States, this one is the 26th largest by enrollment of the 623 interventional ones that give a count, is one of 21 that started in 2008, is one of 62 in phase 3, and was the 86th registered.

Low Back Pain

2,926 studies on the registry are indexed under Low Back Pain; 579 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

99 of the 711 studies in Low Back Pain with a site in United States are open now. Recruiting first, the newest first:

94 more — sign in →

All 99 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 711 studies in Low Back Pain with a site in United States, or all of them as a file.
02

Study summary

To compare the analgesic effectiveness of celecoxib and tramadol in subjects with Chronic Low Back Pain measured by the Numerical Rating Scale (NRS-Pain) at Week 6

03

Conditions studied

  • Low Back Pain

Browse trials for

Keywords

  • Chronic low back pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject presents with duration of chronic low back pain of > 3 months requiring regular use of analgesics (> 4 days/week), except for acetaminophen which cannot have been the sole analgesic used

Exclusion criteria

Exclusion Criteria:

  • The subject has chronic low back pain, which is neurologic in etiology (i.e., radiculopathy, neuropathy, myelopathy)
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
802 participants (actual)

Study arms

  • Experimental
    celecoxib

    Drug: celecoxib

  • Active comparator
    tramadol

    Drug: tramadol HCL

Interventions

06

What researchers measure

Primary outcomes

  1. Treatment Responders Based on the Numerical Rating Scale-Pain (NRS-Pain)

    A subject who met the following criteria was considered as a successful responder at Week 6: completed 6 weeks of treatment with study medication and had a 30% improvement from Baseline to Week 6/ET on the NRS-Pain. NRS-Pain scale assessed the severity of a subject's lower back pain on a scale of 0 (No pain) and 10 (Worst possible pain).

    Time frame: Week 6 or Early Termination (ET)

Secondary outcomes

  1. Change From Baseline in Severity of Chronic Low Back Pain as Measured by NRS-Pain

    NRS-Pain scale assessed the severity of a subject's lower back pain on a scale of 0 (No pain) and 10 (Worst possible pain). NRS-Pain scale: Change = mean score at Week 6/ET minus mean score at Baseline.

    Time frame: Baseline, Week 6/ET

  2. Change From Baseline in Severity of Low Back Pain as Measured by Visual Analogue Scale (VAS)

    VAS was a 100 millimeter (mm) scale that subjects used to assess the severity of their lower back pain. Based on the following question, "During the past day, how much back pain did you have?", the subject was instructed to place a vertical line on the VAS to indicate the magnitude of his/her lower back pain. 0 mm = no pain and 100 mm = worst possible pain. VAS: Change = mean score at Week 6/ET minus mean score at Baseline.

    Time frame: Baseline, Week 6/ET

  3. Patient's Global Assessment of Disease Activity

    Number of subjects with a graded level of disease activity using the Patient's Global Assessment of Disease Activity 5-point scale (1=very good, 2=good, 3=fair, 4=poor, and 5=very poor). Subjects were classified as "Improved" if their assessment reduced at least 2 grades from baseline or if their assessment changed to Grade 1 (Very Good). Subjects were classified as "Worsened" if their assessment increased at least 2 grades from baseline or if their assessment changed to Grade 5 (Very Poor). Subjects were classified as "No Change" otherwise.

    Time frame: Week 6/ET

  4. Physician's Global Assessment of Disease Activity

    Number of subjects with a physician's grading of disease activity using the Physician's Global Assessment of Disease Activity 5-point scale ((1=very good, 2=good, 3=fair, 4=poor, and 5=very poor). Subjects were classified as "Improved" if their assessment reduced at least 2 grades from baseline or if their assessment changed to Grade 1 (Very Good). Subjects were classified as "Worsened" if their assessment increased at least 2 grades from baseline or if their assessment changed to Grade 5 (Very Poor). Subjects were classified as "No Change" otherwise.

    Time frame: Week 6/ET

  5. Change From Baseline in Roland-Morris Disability Questionnaire (RMDQ) Total Score

    Each subject assessed his/her own disability due to low back pain using the RMDQ worksheet, which consisted of 24 statements of disability. The RMDQ total score was calculated as the total number of statements that were checked; the RMDQ total scores could have ranged from 0 to 24, with higher scores indicating greater disability. RMDQ: Change = mean score at Week 6/ET minus mean score at Baseline.

    Time frame: Baseline, Week 6/ET

  6. Change From Baseline in Modified Brief Pain Inventory (m-BPI-sf)

    m-BPI-sf scale assessed pain severity (0 = no pain to 10 = worst possible pain), and pain interference of functional activities (0 = does not interfere to 10 = completely interferes) during the 24 hour follow-up period. Subjects indicated: how much pain now; worst pain; average level of pain; how much pain interfered with general activity, mood, walking ability, relations with other people, sleep, normal work (including housework), and enjoyment of life. m-BPI-sf: Change = mean score at Week 6/ET minus mean score at Baseline.

    Time frame: Baseline, Week 6/ET

  7. Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale

    MOS sleep scale included the following attributes: sleep disturbance, snoring, awaken shortness of breath or headache, quantity of sleep, sleep adequacy, somnolence, Sleep Problem Index I, and Sleep Problem Index II. Score ranged from 0-100, with a higher score indicating more of the scale attribute (e.g., more sleep disturbance, etc.). A negative change indicated subject improvement. MOS sleep scale: Change = mean score at Week 6/ET minus mean score at Baseline.

    Time frame: Baseline, Week 6/ET

  8. Number of Subjects With Change From Baseline in MOS Optimal Sleep Scale Scores

    The Optimal Scale is scaled from 0 or 1 with 1 indicating 7 or 8 hours of sleep per night and 0 otherwise. Number of subjects with change of improvement (0 to 1), no change (1 to 1 or 0 to 0), or worsening (1 to 0) from baseline as indicated by the MOS Optimal sleep scale.

    Time frame: Baseline, Week 6/ET

  9. Change From Baseline in Work Limitations Questionnaire (WLQ)

    The WLQ included the following: Time Scale, Physical Scale, Output Scale, Mental-Interpersonal Scale, and Index Scale. The scales ranged from 0 (Limited none of the time) to 100 (Limited all of the time). A negative change indicated subject improvement.

    Time frame: Baseline, Week 6/ET

  10. Patient's Global Evaluation of Study Medication

    Number of subjects with an overall response to study medication of poor, fair, good, very good, and excellent.

    Time frame: Weeks 1, 3, and 6/ET

  11. Patient's Satisfaction Questionnaire (With Pain Relief Scale)

    Number of subjects at varying levels of pain relief (1 = very dissatisfied to 10 = very satisfied).

    Time frame: Week 6/ET

  12. Patient's Satisfaction Questionnaire (With Walking and Bending Ability Scale)

    Number of subjects at varying levels of pain relief (1 = very dissatisfied to 10 = very satisfied).

    Time frame: Week 6/ET

  13. Chronic Low Back Pain Responders Based on VAS, Patient's Global, and RMDQ

    Subjects were successful responders if they had: \> = 30% improvement from baseline to final visit in VAS assessment (as identified by 100 millimeter scale); \> = 30% improvement from baseline to final visit in Patient's Global assessment (classified as improved if assessment reduced at least 2 grades from baseline or if assessment changed to Grade 1, worsened if assessment increased at least 2 grades from baseline or if assessment changed to Grade 5, or no change; and \< 20% worsening from baseline to final visit in RMDQ assessment (lower scores indicated greater disability).

    Time frame: Week 6/ET

07

Results

Posted Nov 23, 2009

Participant flow

Participant flow — Overall Study
MilestoneCelecoxibTramadol HCL
Started398404
Received treatment396396
Completed342294
Not completed56110
Withdrew: Adverse event2159
Withdrew: Lack of efficacy47
Withdrew: Lost to follow-up1310
Withdrew: Other914
Withdrew: Withdrawal by subject712
Withdrew: Randomized but did not receive treatment28

Outcome measures

PrimaryTreatment Responders Based on the Numerical Rating Scale-Pain (NRS-Pain)

A subject who met the following criteria was considered as a successful responder at Week 6: completed 6 weeks of treatment with study medication and had a 30% improvement from Baseline to Week 6/ET on the NRS-Pain. NRS-Pain scale assessed the severity of a subject's lower back pain on a scale of 0 (No pain) and 10 (Worst possible pain).

Time frame:
Week 6 or Early Termination (ET)
Reported as:
Number · participants
Treatment Responders Based on the Numerical Rating Scale-Pain (NRS-Pain)
participantsCelecoxibTramadol HCL
Responders254218
Non-responders142178
Statistical analysis
  • Celecoxib vs Tramadol HCL · Risk difference (rd): 0.0910 · 95% CI 0.0255 to 0.1565
  • Celecoxib vs Tramadol HCL · Cochran-Mantel-Haenszel · p = 0.008
SecondaryChange From Baseline in Severity of Chronic Low Back Pain as Measured by NRS-Pain

NRS-Pain scale assessed the severity of a subject's lower back pain on a scale of 0 (No pain) and 10 (Worst possible pain). NRS-Pain scale: Change = mean score at Week 6/ET minus mean score at Baseline.

Time frame:
Baseline, Week 6/ET
Reported as:
Mean · scores on a scale
Change From Baseline in Severity of Chronic Low Back Pain as Measured by NRS-Pain
scores on a scaleCelecoxibTramadol HCL
Change From Baseline in Severity of Chronic Low Back Pain as Measured by NRS-Pain-3.38 ± 0.12-3.25 ± 0.13
Statistical analysis
  • Celecoxib vs Tramadol HCL · ANCOVA · p = 0.234 · Mean difference (final values): -0.20 · 95% CI -0.53 to 0.13The mean difference reported is the least squares (LS) mean difference.
SecondaryChange From Baseline in Severity of Low Back Pain as Measured by Visual Analogue Scale (VAS)

VAS was a 100 millimeter (mm) scale that subjects used to assess the severity of their lower back pain. Based on the following question, "During the past day, how much back pain did you have?", the subject was instructed to place a vertical line on the VAS to indicate the magnitude of his/her lower back pain. 0 mm = no pain and 100 mm = worst possible pain. VAS: Change = mean score at Week 6/ET minus mean score at Baseline.

Time frame:
Baseline, Week 6/ET
Reported as:
Mean · mm
Change From Baseline in Severity of Low Back Pain as Measured by Visual Analogue Scale (VAS)
mmCelecoxibTramadol HCL
Change From Baseline in Severity of Low Back Pain as Measured by Visual Analogue Scale (VAS)-34.78 ± 1.33-34.27 ± 1.42
Statistical analysis
  • Celecoxib vs Tramadol HCL · ANCOVA · p = 0.595 · Mean difference (final values): -0.94 · 95% CI -4.39 to 2.52The mean difference reported is the LS mean difference.
SecondaryPatient's Global Assessment of Disease Activity

Number of subjects with a graded level of disease activity using the Patient's Global Assessment of Disease Activity 5-point scale (1=very good, 2=good, 3=fair, 4=poor, and 5=very poor). Subjects were classified as "Improved" if their assessment reduced at least 2 grades from baseline or if their assessment changed to Grade 1 (Very Good). Subjects were classified as "Worsened" if their assessment increased at least 2 grades from baseline or if their assessment changed to Grade 5 (Very Poor). Subjects were classified as "No Change" otherwise.

Time frame:
Week 6/ET
Reported as:
Number · participants
Patient's Global Assessment of Disease Activity
participantsCelecoxibTramadol HCL
Improved108107
No Change264259
Worsened31
Statistical analysis
  • Celecoxib vs Tramadol HCL · Cochran-Mantel-Haenszel · p = 0.829
SecondaryPhysician's Global Assessment of Disease Activity

Number of subjects with a physician's grading of disease activity using the Physician's Global Assessment of Disease Activity 5-point scale ((1=very good, 2=good, 3=fair, 4=poor, and 5=very poor). Subjects were classified as "Improved" if their assessment reduced at least 2 grades from baseline or if their assessment changed to Grade 1 (Very Good). Subjects were classified as "Worsened" if their assessment increased at least 2 grades from baseline or if their assessment changed to Grade 5 (Very Poor). Subjects were classified as "No Change" otherwise.

Time frame:
Week 6/ET
Reported as:
Number · participants
Physician's Global Assessment of Disease Activity
participantsCelecoxibTramadol HCL
Improved113102
No Change253258
Worsened21
Statistical analysis
  • Celecoxib vs Tramadol HCL · Cochran-Mantel-Haenszel · p = 0.470
SecondaryChange From Baseline in Roland-Morris Disability Questionnaire (RMDQ) Total Score

Each subject assessed his/her own disability due to low back pain using the RMDQ worksheet, which consisted of 24 statements of disability. The RMDQ total score was calculated as the total number of statements that were checked; the RMDQ total scores could have ranged from 0 to 24, with higher scores indicating greater disability. RMDQ: Change = mean score at Week 6/ET minus mean score at Baseline.

Time frame:
Baseline, Week 6/ET
Reported as:
Mean · scores on a scale
Change From Baseline in Roland-Morris Disability Questionnaire (RMDQ) Total Score
scores on a scaleCelecoxibTramadol HCL
Change From Baseline in Roland-Morris Disability Questionnaire (RMDQ) Total Score-4.90 ± 0.26-4.45 ± 0.25
Statistical analysis
  • Celecoxib vs Tramadol HCL · ANCOVA · p = 0.339 · Mean difference (final values): -0.31 · 95% CI -0.95 to 0.33The mean difference reported is the LS mean difference.
SecondaryChange From Baseline in Modified Brief Pain Inventory (m-BPI-sf)

m-BPI-sf scale assessed pain severity (0 = no pain to 10 = worst possible pain), and pain interference of functional activities (0 = does not interfere to 10 = completely interferes) during the 24 hour follow-up period. Subjects indicated: how much pain now; worst pain; average level of pain; how much pain interfered with general activity, mood, walking ability, relations with other people, sleep, normal work (including housework), and enjoyment of life. m-BPI-sf: Change = mean score at Week 6/ET minus mean score at Baseline.

Time frame:
Baseline, Week 6/ET
Reported as:
Mean · scores on a scale
Change From Baseline in Modified Brief Pain Inventory (m-BPI-sf)
scores on a scaleCelecoxibTramadol HCL
How Much Pain Now-2.87 ± 0.12-2.88 ± 0.13
Worst Pain in Past 24 Hours-2.84 ± 0.13-2.87 ± 0.13
Average Pain in Past 24 Hours-2.64 ± 0.11-2.59 ± 0.13
Pain Interfered With General Activity-2.62 ± 0.12-2.57 ± 0.13
Pain Interfered With Mood-2.38 ± 0.14-2.25 ± 0.15
Pain Interfered With Walking Activity-2.26 ± 0.13-2.36 ± 0.13
Pain Interfered With Relations With Others-1.79 ± 0.13-1.74 ± 0.14
Pain Interfered With Sleep-2.52 ± 0.13-2.51 ± 0.15
Pain Interfered With Normal Work-2.57 ± 0.13-2.46 ± 0.15
Pain Interfered With Enjoyment of Life-2.43 ± 0.14-2.43 ± 0.15
Pain Interference Subscale-2.37 ± 0.11-2.33 ± 0.12
Statistical analysis
  • Celecoxib vs Tramadol HCL · ANCOVA · p = 0.741 · Mean difference (final values): -0.05 · 95% CI -0.36 to 0.25The mean difference reported is the LS mean difference.
  • Celecoxib vs Tramadol HCL · ANCOVA · p = 0.796 · Mean difference (final values): -0.04 · 95% CI -0.38 to 0.29The mean difference reported is the LS mean difference.
  • Celecoxib vs Tramadol HCL · ANCOVA · p = 0.492 · Mean difference (final values): -0.11 · 95% CI -0.41 to 0.20The mean difference reported is the LS mean difference.
  • Celecoxib vs Tramadol HCL · ANCOVA · p = 0.893 · Mean difference (final values): 0.02 · 95% CI -0.28 to 0.33The mean difference reported is the LS mean difference.
  • Celecoxib vs Tramadol HCL · ANCOVA · p = 0.618 · Mean difference (final values): -0.08 · 95% CI -0.40 to 0.24The mean difference reported is the LS mean difference.
  • Celecoxib vs Tramadol HCL · ANCOVA · p = 0.440 · Mean difference (final values): 0.12 · 95% CI -0.19 to 0.43The mean difference reported is the LS mean difference.
  • Celecoxib vs Tramadol HCL · ANCOVA · p = 0.806 · Mean difference (final values): 0.04 · 95% CI -0.25 to 0.32The mean difference reported is the LS mean difference.
  • Celecoxib vs Tramadol HCL · ANCOVA · p = 0.739 · Mean difference (final values): -0.05 · 95% CI -0.38 to 0.27The mean difference reported is the LS mean difference.
  • Celecoxib vs Tramadol HCL · ANCOVA · p = 0.992 · Mean difference (final values): 0.00 · 95% CI -0.32 to 0.33The mean difference reported is the LS mean difference.
  • Celecoxib vs Tramadol HCL · ANCOVA · p = 0.793 · Mean difference (final values): 0.04 · 95% CI -0.28 to 0.36The mean difference reported is the LS mean difference.
  • Celecoxib vs Tramadol HCL · ANCOVA · p = 0.973 · Mean difference (final values): 0.00 · 95% CI -0.27 to 0.28The mean difference reported is the LS mean difference.
SecondaryChange From Baseline in Medical Outcomes Study (MOS) Sleep Scale

MOS sleep scale included the following attributes: sleep disturbance, snoring, awaken shortness of breath or headache, quantity of sleep, sleep adequacy, somnolence, Sleep Problem Index I, and Sleep Problem Index II. Score ranged from 0-100, with a higher score indicating more of the scale attribute (e.g., more sleep disturbance, etc.). A negative change indicated subject improvement. MOS sleep scale: Change = mean score at Week 6/ET minus mean score at Baseline.

Time frame:
Baseline, Week 6/ET
Reported as:
Mean · scores on a scale
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale
scores on a scaleCelecoxibTramadol HCL
Sleep Disturbance (n=374, 367)-17.91 ± 1.23-16.34 ± 1.17
Snoring (n=372, 365)-7.53 ± 1.31-5.10 ± 1.28
Awaken Shortness of Breath, Headache (n=374, 367)-8.61 ± 1.27-6.21 ± 1.34
Quantity of Sleep (n=373, 365)0.00 ± 0.230.58 ± 0.28
Sleep Adequacy (n=373, 367)7.32 ± 1.489.67 ± 1.34
Somnolence (n=374, 366)-9.63 ± 1.05-7.01 ± 1.16
Sleep Problem Index I (n=373, 367)-11.59 ± 0.96-10.54 ± 0.92
Sleep Problem Index II (n=373, 367)-12.97 ± 0.94-11.82 ± 0.89
Statistical analysis
  • Celecoxib vs Tramadol HCL · ANCOVA · p = 0.392 · Mean difference (final values): -1.29 · 95% CI -4.26 to 1.67The mean difference reported is the LS mean difference.
  • Celecoxib vs Tramadol HCL · ANCOVA · p = 0.691 · Mean difference (final values): -0.66 · 95% CI -3.94 to 2.61The mean difference reported is the LS mean difference.
  • Celecoxib vs Tramadol HCL · ANCOVA · p = 0.549 · Mean difference (final values): -0.87 · 95% CI -3.70 to 1.97The mean difference reported is the LS mean difference.
  • Celecoxib vs Tramadol HCL · ANCOVA · p = 0.336 · Mean difference (final values): -0.22 · 95% CI -0.67 to 0.23The mean difference reported is the LS mean difference.
  • Celecoxib vs Tramadol HCL · ANCOVA · p = 0.370 · Mean difference (final values): -1.51 · 95% CI -4.83 to 1.80The mean difference reported is the LS mean difference.
  • Celecoxib vs Tramadol HCL · ANCOVA · p = 0.341 · Mean difference (final values): -1.27 · 95% CI -3.90 to 1.35The mean difference reported is the LS mean difference.
  • Celecoxib vs Tramadol HCL · ANCOVA · p = 0.604 · Mean difference (final values): -0.59 · 95% CI -2.85 to 1.66The mean difference reported is the LS mean difference.
  • Celecoxib vs Tramadol HCL · ANCOVA · p = 0.547 · Mean difference (final values): -0.68 · 95% CI -2.92 to 1.55The mean difference reported is the LS mean difference.
SecondaryNumber of Subjects With Change From Baseline in MOS Optimal Sleep Scale Scores

The Optimal Scale is scaled from 0 or 1 with 1 indicating 7 or 8 hours of sleep per night and 0 otherwise. Number of subjects with change of improvement (0 to 1), no change (1 to 1 or 0 to 0), or worsening (1 to 0) from baseline as indicated by the MOS Optimal sleep scale.

Time frame:
Baseline, Week 6/ET
Reported as:
Number · participants
Number of Subjects With Change From Baseline in MOS Optimal Sleep Scale Scores
participantsCelecoxibTramadol HCL
0 to 1 (Improvement)8274
1 to 1 (No change)9470
0 to 0 (No change)171192
1 to 0 (worsening)2629
Statistical analysis
  • Celecoxib vs Tramadol HCL · Cochran-Mantel-Haenszel · p = 0.196
SecondaryChange From Baseline in Work Limitations Questionnaire (WLQ)

The WLQ included the following: Time Scale, Physical Scale, Output Scale, Mental-Interpersonal Scale, and Index Scale. The scales ranged from 0 (Limited none of the time) to 100 (Limited all of the time). A negative change indicated subject improvement.

Time frame:
Baseline, Week 6/ET
Reported as:
Mean · scores on a scale
Change From Baseline in Work Limitations Questionnaire (WLQ)
scores on a scaleCelecoxibTramadol HCL
Time Scale (n=241, 239)-11.55 ± 1.65-13.58 ± 1.52
Physical Scale (n=270, 254)-13.68 ± 1.52-12.65 ± 1.45
Output Scale (n=256, 246)-11.44 ± 1.54-11.69 ± 1.70
Mental-Interpersonal Scale (n=266, 252)-9.06 ± 1.35-9.54 ± 1.51
Index Scale (n=223, 220)-3.10 ± 0.36-3.14 ± 0.37
Statistical analysis
  • Celecoxib vs Tramadol HCL · ANCOVA · p = 0.252 · Mean difference (final values): 2.19 · 95% CI -1.56 to 5.94The mean difference reported is the LS mean difference.
  • Celecoxib vs Tramadol HCL · ANCOVA · p = 0.798 · Mean difference (final values): 0.48 · 95% CI -3.21 to 4.17The mean difference reported is the LS mean difference.
  • Celecoxib vs Tramadol HCL · ANCOVA · p = 0.700 · Mean difference (final values): 0.74 · 95% CI -3.03 to 4.51The mean difference reported is the LS mean difference.
  • Celecoxib vs Tramadol HCL · ANCOVA · p = 0.902 · Mean difference (final values): 0.21 · 95% CI -3.16 to 3.59The mean difference reported is the LS mean difference.
  • Celecoxib vs Tramadol HCL · ANCOVA · p = 0.581 · Mean difference (final values): 0.25 · 95% CI -0.65 to 1.16The mean difference reported is the LS mean difference.
SecondaryPatient's Global Evaluation of Study Medication

Number of subjects with an overall response to study medication of poor, fair, good, very good, and excellent.

Time frame:
Weeks 1, 3, and 6/ET
Reported as:
Number · participants
Patient's Global Evaluation of Study Medication
participantsCelecoxibTramadol HCL
Week 1, Excellent4638
Week 1, Very Good9783
Week 1, Good126137
Week 1, Fair7857
Week 1, Poor2318
Week 3, Excellent5241
Week 3, Very Good10497
Week 3, Good122105
Week 3, Fair5351
Week 3, Poor2314
Week 6/ET, Excellent9168
Week 6/ET, Very Good123112
Week 6/ET, Good7690
Week 6/ET, Fair5151
Week 6/ET, Poor3244
Statistical analysis
  • Celecoxib vs Tramadol HCL · Cochran-Mantel-Haenszel · p = 0.614
  • Celecoxib vs Tramadol HCL · Cochran-Mantel-Haenszel · p = 0.786
  • Celecoxib vs Tramadol HCL · Cochran-Mantel-Haenszel · p = 0.044
SecondaryPatient's Satisfaction Questionnaire (With Pain Relief Scale)

Number of subjects at varying levels of pain relief (1 = very dissatisfied to 10 = very satisfied).

Time frame:
Week 6/ET
Reported as:
Number · participants
Patient's Satisfaction Questionnaire (With Pain Relief Scale)
participantsCelecoxibTramadol HCL
12322
21518
32219
42220
54430
62329
72139
86356
95362
108769
Statistical analysis
  • Celecoxib vs Tramadol HCL · Cochran-Mantel-Haenszel · p = 0.870
SecondaryPatient's Satisfaction Questionnaire (With Walking and Bending Ability Scale)

Number of subjects at varying levels of pain relief (1 = very dissatisfied to 10 = very satisfied).

Time frame:
Week 6/ET
Reported as:
Number · participants
Patient's Satisfaction Questionnaire (With Walking and Bending Ability Scale)
participantsCelecoxibTramadol HCL
12415
21622
31920
43133
53540
63230
73537
85546
95677
107044
Statistical analysis
  • Celecoxib vs Tramadol HCL · Cochran-Mantel-Haenszel · p = 0.545
SecondaryChronic Low Back Pain Responders Based on VAS, Patient's Global, and RMDQ

Subjects were successful responders if they had: \> = 30% improvement from baseline to final visit in VAS assessment (as identified by 100 millimeter scale); \> = 30% improvement from baseline to final visit in Patient's Global assessment (classified as improved if assessment reduced at least 2 grades from baseline or if assessment changed to Grade 1, worsened if assessment increased at least 2 grades from baseline or if assessment changed to Grade 5, or no change; and \< 20% worsening from baseline to final visit in RMDQ assessment (lower scores indicated greater disability).

Time frame:
Week 6/ET
Reported as:
Number · participants
Chronic Low Back Pain Responders Based on VAS, Patient's Global, and RMDQ
participantsCelecoxibTramadol HCL
Responders213196
Non-responders183200
Statistical analysis
  • Celecoxib vs Tramadol HCL · Cochran-Mantel-Haenszel · p = 0.218

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Celecoxib———
Tramadol HCL———
Most frequent serious events
Most frequent serious events
EventCelecoxibTramadol HCL
Coronary artery bypassSurgical and medical procedures1/3960/396
Most frequent other events
Most frequent other events
EventCelecoxibTramadol HCL
NauseaGastrointestinal disorders31/39670/396
HeadacheNervous system disorders41/39654/396
DizzinessNervous system disorders19/39653/396
SomnolenceNervous system disorders20/39644/396
VomitingGastrointestinal disorders5/39628/396
ConstipationGastrointestinal disorders8/39625/396
PruritusSkin and subcutaneous tissue disorders2/39623/396
Dry mouthGastrointestinal disorders6/39620/396

Baseline characteristics

Age, Customized
Age, Customized(participants)CelecoxibTramadol HCLTotal
18 to 44 years164167331
45 to 64 years191182373
> = 65 years414788
Sex: Female, Male
Sex: Female, Male(Participants)CelecoxibTramadol HCLTotal
Female237213450
Male159183342
08

Study locations

60 sites
  • Pfizer Investigational Site
    Birmingham, Alabama 35126, United States
  • Pfizer Investigational Site
    Birmingham, Alabama 35235, United States
  • Pfizer Investigational Site
    Birmingham, Alabama 35242, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85023, United States
  • Pfizer Investigational Site
    Little Rock, Arkansas 72205, United States
  • Pfizer Investigational Site
    Anaheim, California 92801, United States
  • Pfizer Investigational Site
    Long Beach, California 90806, United States
  • Pfizer Investigational Site
    Oceanside, California 92056, United States
  • Pfizer Investigational Site
    Sacramento, California 95823, United States
  • Pfizer Investigational Site
    Sacramento, California 95825, United States
  • Pfizer Investigational Site
    Wildomar, California 92595, United States
  • Pfizer Investigational Site
    Boulder, Colorado 80304, United States
  • Pfizer Investigational Site
    Colorado Springs, Colorado 80904, United States
  • Pfizer Investigational Site
    Denver, Colorado 80220, United States
  • Pfizer Investigational Site
    Cos Cob, Connecticut 06807, United States
  • Pfizer Investigational Site
    Jacksonville, Florida 32216, United States
  • Pfizer Investigational Site
    Jacksonville, Florida 32257, United States
  • Pfizer Investigational Site
    Pinellas Park, Florida 33781, United States
  • Pfizer Investigational Site
    West Palm Beach, Florida 33409, United States
  • Pfizer Investigational Site
    Woodstock, Georgia 30189, United States
  • Pfizer Investigational Site
    Wichita, Kansas 67206, United States
  • Pfizer Investigational Site
    Wichita, Kansas 67214, United States
  • Pfizer Investigational Site
    Baton Rouge, Louisiana 70809, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21218, United States
  • Pfizer Investigational Site
    Columbia, Maryland 21045, United States
  • Pfizer Investigational Site
    Rockville, Maryland 20852, United States
  • Pfizer Investigational Site
    Wheaton, Maryland 20902, United States
  • Pfizer Investigational Site
    Saint Paul, Minnesota 55108, United States
  • Pfizer Investigational Site
    Jackson, Mississippi 39202, United States
  • Pfizer Investigational Site
    Saint Louis, Missouri 63141, United States
  • Pfizer Investigational Site
    Springfield, Missouri 65807, United States
  • Pfizer Investigational Site
    Omaha, Nebraska 68134, United States
  • Pfizer Investigational Site
    New Windsor, New York 12553, United States
  • Pfizer Investigational Site
    New York, New York 10022-1009, United States
  • Pfizer Investigational Site
    Rochester, New York 14618, United States
  • Pfizer Investigational Site
    Williamsville, New York 14221, United States
  • Pfizer Investigational Site
    Portland, Oregon 97219, United States
  • Pfizer Investigational Site
    Bridgeville, Pennsylvania 15017, United States
  • Pfizer Investigational Site
    Camp Hill, Pennsylvania 17011, United States
  • Pfizer Investigational Site
    Columbia, South Carolina 29204, United States
  • Pfizer Investigational Site
    North Charleston, South Carolina 29406, United States
  • Pfizer Investigational Site
    Bristol, Tennessee 37620, United States
  • Pfizer Investigational Site
    Collierville, Tennessee 38017, United States
  • Pfizer Investigational Site
    Johnson City, Tennessee 37601, United States
  • Pfizer Investigational Site
    Kingsport, Tennessee 37660, United States
  • Pfizer Investigational Site
    New Tazewell, Tennessee 37825, United States
  • Pfizer Investigational Site
    Austin, Texas 78705, United States
  • Pfizer Investigational Site
    Beaumont, Texas 77701, United States
  • Pfizer Investigational Site
    Beaumont, Texas 77706, United States
  • Pfizer Investigational Site
    Dallas, Texas 75230, United States
  • Pfizer Investigational Site
    Dallas, Texas 75240, United States
  • Pfizer Investigational Site
    Grapevine, Texas 76051, United States
  • Pfizer Investigational Site
    Houston, Texas 77074, United States
  • Pfizer Investigational Site
    Lake Jackson, Texas 77566, United States
  • Pfizer Investigational Site
    San Angelo, Texas 76904, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78217, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78229, United States
  • Pfizer Investigational Site
    Salt Lake City, Utah 84107, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23294, United States
  • Pfizer Investigational Site
    Weber City, Virginia 24290, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2009, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2007
First posted
Apr 21, 2008
Start
Jan 2008
Primary completionActual
Sep 2008
CompletionActual
Sep 2008
Results first posted
Nov 23, 2009
Last update
Feb 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00662558
Responsible party
Sponsor
First posted
Apr 21, 2008
Start date
Jan 2008
Primary completion
Sep 2008
Completion
Sep 2008
Results posted
Nov 23, 2009
Last update
Feb 21, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion